Drug intelligence / Profile preview

methapyrilene

Development stage
Phase 3
Lead developer
Abbott
Modality
Small Molecules
Administration
Oral, Topical, Ophthalmic, Intravenous, Intramuscular
01

Overview

Methapyrilene is a first-generation ethylenediamine H1-antihistamine and anticholinergic of the pyridine chemical class developed in the early 1950s. It was primarily used for its sedative effects to treat insomnia and as an anti-allergic agent. Methapyrilene acts as a histamine H1 receptor antagonist by interfering with the agonist action of histamine at the H1 receptor, thereby attenuating inflammatory processes such as allergic rhinitis and urticaria. It also exhibits anticholinergic properties. The drug readily crosses the blood-brain barrier and causes significant sedation. Methapyrilene was withdrawn from markets worldwide in 1979 after it was shown to be a potent carcinogen causing liver cancer in animal studies[1][3][4][6].

Brand names
Co-PyronilHistadyl ECSominexNytolSleep-EzeExcedrin PM
Other names
methapyrilene hydrochloridemethapyrilene fumarate
02

Targets

mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on methapyrilene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methapyrilene.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call